Literature DB >> 22647690

Drug-drug interaction through molecular structure similarity analysis.

Santiago Vilar1, Rave Harpaz, Eugenio Uriarte, Lourdes Santana, Raul Rabadan, Carol Friedman.   

Abstract

BACKGROUND: Drug-drug interactions (DDIs) are responsible for many serious adverse events; their detection is crucial for patient safety but is very challenging. Currently, the US Food and Drug Administration and pharmaceutical companies are showing great interest in the development of improved tools for identifying DDIs.
METHODS: We present a new methodology applicable on a large scale that identifies novel DDIs based on molecular structural similarity to drugs involved in established DDIs. The underlying assumption is that if drug A and drug B interact to produce a specific biological effect, then drugs similar to drug A (or drug B) are likely to interact with drug B (or drug A) to produce the same effect. DrugBank was used as a resource for collecting 9454 established DDIs. The structural similarity of all pairs of drugs in DrugBank was computed to identify DDI candidates.
RESULTS: The methodology was evaluated using as a gold standard the interactions retrieved from the initial DrugBank database. Results demonstrated an overall sensitivity of 0.68, specificity of 0.96, and precision of 0.26. Additionally, the methodology was also evaluated in an independent test using the Micromedex/Drugdex database.
CONCLUSION: The proposed methodology is simple, efficient, allows the investigation of large numbers of drugs, and helps highlight the etiology of DDI. A database of 58 403 predicted DDIs with structural evidence is provided as an open resource for investigators seeking to analyze DDIs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22647690      PMCID: PMC3534468          DOI: 10.1136/amiajnl-2012-000935

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  30 in total

1.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

2.  Novel 2D fingerprints for ligand-based virtual screening.

Authors:  Todd Ewing; J Christian Baber; Miklos Feher
Journal:  J Chem Inf Model       Date:  2006 Nov-Dec       Impact factor: 4.956

3.  Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action.

Authors:  Santiago Vilar; Lourdes Santana; Eugenio Uriarte
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

4.  Quantifying the relationships among drug classes.

Authors:  Jérôme Hert; Michael J Keiser; John J Irwin; Tudor I Oprea; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2008-03-13       Impact factor: 4.956

5.  A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists.

Authors:  Stanislav Engel; Amanda P Skoumbourdis; John Childress; Susanne Neumann; Jeffrey R Deschamps; Craig J Thomas; Anny-Odile Colson; Stefano Costanzi; Marvin C Gershengorn
Journal:  J Am Chem Soc       Date:  2008-03-22       Impact factor: 15.419

6.  The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.

Authors:  D W Bates; N Spell; D J Cullen; E Burdick; N Laird; L A Petersen; S D Small; B J Sweitzer; L L Leape
Journal:  JAMA       Date:  1997 Jan 22-29       Impact factor: 56.272

7.  Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units.

Authors:  D J Cullen; B J Sweitzer; D W Bates; E Burdick; A Edmondson; L L Leape
Journal:  Crit Care Med       Date:  1997-08       Impact factor: 7.598

8.  Relating protein pharmacology by ligand chemistry.

Authors:  Michael J Keiser; Bryan L Roth; Blaine N Armbruster; Paul Ernsberger; John J Irwin; Brian K Shoichet
Journal:  Nat Biotechnol       Date:  2007-02       Impact factor: 54.908

9.  The incident reporting system does not detect adverse drug events: a problem for quality improvement.

Authors:  D J Cullen; D W Bates; S D Small; J B Cooper; A R Nemeskal; L L Leape
Journal:  Jt Comm J Qual Improv       Date:  1995-10

10.  Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.

Authors:  Espen Molden; Eva Skovlund; Pia Braathen
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more
  49 in total

1.  Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities.

Authors:  Marinka Zitnik; Francis Nguyen; Bo Wang; Jure Leskovec; Anna Goldenberg; Michael M Hoffman
Journal:  Inf Fusion       Date:  2018-09-21       Impact factor: 12.975

2.  Similarity-based modeling in large-scale prediction of drug-drug interactions.

Authors:  Santiago Vilar; Eugenio Uriarte; Lourdes Santana; Tal Lorberbaum; George Hripcsak; Carol Friedman; Nicholas P Tatonetti
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

3.  Text Mining Driven Drug-Drug Interaction Detection.

Authors:  Su Yan; Xiaoqian Jiang; Ying Chen
Journal:  Proceedings (IEEE Int Conf Bioinformatics Biomed)       Date:  2013

4.  Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties.

Authors:  Feixiong Cheng; Zhongming Zhao
Journal:  J Am Med Inform Assoc       Date:  2014-03-18       Impact factor: 4.497

5.  The role of drug profiles as similarity metrics: applications to repurposing, adverse effects detection and drug-drug interactions.

Authors:  Santiago Vilar; George Hripcsak
Journal:  Brief Bioinform       Date:  2017-07-01       Impact factor: 11.622

6.  Finding Causal Mechanistic Drug-Drug Interactions from Observational Data.

Authors:  Sanjoy Dey; Ping Zhang; Mohamed Ghalwash; Chandramouli Maduri; Daby Sow; Zach Shahn
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

7.  Deep learning improves prediction of drug-drug and drug-food interactions.

Authors:  Jae Yong Ryu; Hyun Uk Kim; Sang Yup Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-16       Impact factor: 11.205

Review 8.  Informatics confronts drug-drug interactions.

Authors:  Bethany Percha; Russ B Altman
Journal:  Trends Pharmacol Sci       Date:  2013-02-13       Impact factor: 14.819

9.  Mining clinical text for signals of adverse drug-drug interactions.

Authors:  Srinivasan V Iyer; Rave Harpaz; Paea LePendu; Anna Bauer-Mehren; Nigam H Shah
Journal:  J Am Med Inform Assoc       Date:  2013-10-24       Impact factor: 4.497

10.  Drug-Drug Interaction Discovery: Kernel Learning from Heterogeneous Similarities.

Authors:  Devendra Singh Dhami; Gautam Kunapuli; Mayukh Das; David Page; Sriraam Natarajan
Journal:  Smart Health (Amst)       Date:  2018-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.